CDK4/6 inhibitor selection eLearning

Barbara, Juanita and Emma have all been diagnosed with HR+/HER2- metastatic breast cancer and have been prescribed a CDK4/6 inhibitor. Can you help us select the optimal CDK4/6 inhibitor for each of our three patients?

Course overview

This interactive ‘CDK4/6 inhibitor selection’ eLearning module was developed together with Dr Gregory Vidal, a medical oncologist and researcher from the West Cancer Center and Research Institute, USA. Using three example patient case studies, the module highlights the key differences between abemaciclib, palbociclib and ribociclib that may impact the choice of CDK4/6 inhibitor for your patient. Some differentiators discussed include:

• disease characteristics (for example, central nervous system and visceral involvement)
• patient characteristics (menopausal status and other health issues)
• safety and tolerance (adverse events and monitoring)

System Requirements

Faculty

Dr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center, USA. Dr Vidal trained as a clinical researcher at the University of Stanford, and the aim of his research is to discover and develop safe and effective treatments for breast cancer.

Further information

For more information on selecting the optimal CDK4/6 inhibitor for your patient, visit our pages on CDK4/6 inhibitor selection, where you will also find expert video interviews on the topic.